GENE ONLINE|News &
Opinion
Blog

Hemophilia B
Trials & Approvals Gene Therapy
CSL’s Hemgenix Wins First Gene Therapy Approval For Hemophilia In Europe
2023-02-21
Trials & Approvals Hemophilia B
Pfizer’s Hemophilia B Gene Therapy Meets Phase 3 Endpoints
2022-12-30
Trials & Approvals Gene Therapy
Hemgenix Marks Most Expensive Treatment Ever and First Gene Therapy for Hemophilia B
2022-11-22
Interviews Hemophilia B
The Transformative Potential of Gene Therapies for Hemophilia
2021-04-08
Trials & Approvals HOPE-B Trial
uniQure’s Inquiry Shows Hemophilia B Gene Therapy not Likely to Have Induced Liver Cancer
2021-03-30
Trials & Approvals
uniQure’s Hemophilia B Gene Therapy Put on Clinical Hold by the FDA
2020-12-22
Hemophilia B
CSL Behring to Tackle Hemophilia B Using UniQure’s Gene Therapy Program
2020-06-28
LATEST
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
READ MORE
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top